Skip to main content
. 2018 Mar 12;200(8):2542–2553. doi: 10.4049/jimmunol.1701171

FIGURE 5.

FIGURE 5.

Therapeutic effect of Fc-μTP-L309C in chronic autoimmune arthritis. (A) Protocol for evaluating therapeutic efficacy in CIA. (B) Clinical response to therapeutic administration of Fc-μTP-L309C (200 mg/kg) or IVIG (2000 mg/kg) at the days indicated (arrows). PBS served as control. Kinetics of response (left) and mean clinical scores over days 2–28 (right) are shown (n = 6–8 mice). (C) Histopathology of arthritic joints. Representative H&E-stained sections of ankle joints from arthritic mice at day 28 of disease. Joints from IVIG-treated mice (data not shown) appeared similar to the Fc-μTP-L309C group. Original magnification ×40. (D) Histological analysis of joints. Data show the mean (± SEM) histological scores of joints (n = 12–16) at day 28 of disease. *p < 0.05, **p < 0.01 compared with PBS control, Kruskal–Wallis with Dunn test.